首页> 外文期刊>Hematological oncology >Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6‐positive double‐hit DLBCL treated with lenalidomide monotherapy
【24h】

Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6‐positive double‐hit DLBCL treated with lenalidomide monotherapy

机译:耐用的缓解患者,患有Myc / Bcl6阳性双击DLBCL的百分之肌擦伤,用Lenalidomide单药治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B‐cell lymphoma and presents as leptomeningeal dissemination in two‐thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication. Here we present the first case, to our knowledge, of a MYC/BCL6‐positive double‐hit diffuse large B‐cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single‐agent lenalidomide following salvage chemotherapy. Copyright ? 2016 John Wiley & Sons, Ltd.
机译:摘要继发性中枢神经系统受累是一种罕见的疾病,通常发生在弥漫性大B细胞淋巴瘤的自然史早期,三分之二的病例表现为软脑膜播散。这一事件的预后很差,治疗选择也很少。虽然中枢神经系统播散的主要风险因素是临床因素,但伴随的MYC/BCL2重排以及MYC/BCL2蛋白表达最近与该并发症的风险增加有关。据我们所知,这里我们介绍了第一例MYC/BCL6阳性双击弥漫性大B细胞淋巴瘤在软脑膜复发的病例,在挽救性化疗后,单药来那度胺取得了显著的持久缓解。版权2016年约翰·威利;儿子有限公司。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号